U.S. Markets close in 1 hr 18 mins

Biogen stock hit hard after company pulls Alzheimer’s drug

Biogen stock is tanking after scrapping an Alzheimer’s drug in its phase 3 trial. Yahoo Finance’s Dan Roberts, Akiko Fujita, Sibile Marcellus, and Heidi Chung discuss the impact of this change for the drug manufacturer.